Abstract Overview: Effect of IL-2 Cytokine Immune Agonist (NKTR-214) 

Abstract Overview: Effect of IL-2 Cytokine Immune Agonist (NKTR-214) 

AnnualMeeting2017

2 years
764 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Adi Diab, MD of MD Anderson Cancer Center gives an overview of his abstracts, which focus on the use of NKTR-214 for treatment of patients with renal cell carcinoma and melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract e14040: A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors

Abstract 2545: Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy
Up Next Autoplay